Firebrick Pharma withdraws share placement
Key points
- Firebrick Pharma decides not to proceed with proposed share placement
- Trading halt lodged on 5 June 2025 has been lifted
- Nasodine Nasal Spray commercialized in US, Singapore, Fiji and Philippines
Full summary
Firebrick Pharma Limited (ASX:FRE) has announced the withdrawal of its proposed share placement. The company had previously requested a trading halt on 5 June 2025, but the Board has now decided not to proceed with the placement at this time. Firebrick is a pharmaceutical innovator developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has developed and is now commercializing Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick recently introduced Nasodine in the United States, Singapore, Fiji, and the South Pacific, with an agreement in place to also manufacture and launch Nasodine in the Philippines.
Summary generated by a large language model. Please interpret with care.